Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Ciclesonide

FDA-approved product (aerosol, metered, inhalation), marketed as Alvesco, Omnaris, Zetonna.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Ciclesonide
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Airway obstruction
  • Allergic rhinitis
  • Asthma
  • Nasal congestion
  • Rhinitis, Allergic, Perennial
  • Seasonal allergic rhinitis

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Corticosteroids; Glucocorticoids
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA and E. coli. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA60.7% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli40.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae29.9% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis36.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Ciclesonide in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-9.8 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.7 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-9.1 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-8.5 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Ciclesonide with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Individualizing Treatment for Asthma in Primary Care

    NCT06272370 · start 2024-02-01

    Registered record
    Registry ID
    NCT06272370
    Conditions
    Asthma; Bronchial Diseases; Respiratory Tract Infections; Lung Diseases, Obstructive; Lung Diseases; Respiratory Hypersensitivity; Immune System Diseases
    Interventions
    Asthma Symptom Monitoring online tools; Inhaled Steroids; Azithromycin Pill
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2024-02-01
    Completion
    2024-12-31
    Enrolment
    103

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAsthma; Bronchial Diseases; Respiratory Tract Infections; Lung Diseases, Obstructive +3 more
    InterventionAsthma Symptom Monitoring online tools; Inhaled Steroids; Azithromycin Pill
    PhasePhase 4
    Registry statusCompleted

  • PROphylaxis for paTiEnts at Risk of COVID-19 infecTion -V

    NCT04870333 · start 2021-02-19

    Registered record
    Registry ID
    NCT04870333
    Conditions
    Covid19
    Interventions
    Niclosamide; Placebo; Ciclesonide; Placebo; Sotrovimab; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Completed
    Start
    2021-02-19
    Completion
    2025-04-16
    Enrolment
    2,240

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCovid19
    InterventionNiclosamide; Placebo; Ciclesonide; Placebo +2 more
    PhasePhase 2 / Phase 3
    Registry statusCompleted

  • Inhaled Ciclesonide for Outpatients With COVID19

    NCT04435795 · start 2020-09-15

    Registered record
    Registry ID
    NCT04435795
    Conditions
    COVID 19
    Interventions
    Normal Saline intranasal and placebo inhaler; Ciclesonide; Ciclesonide nasal
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Terminated
    Start
    2020-09-15
    Completion
    2021-07-08
    Enrolment
    215

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCOVID 19
    InterventionNormal Saline intranasal and placebo inhaler; Ciclesonide; Ciclesonide nasal
    PhasePhase 2 / Phase 3
    Registry statusTerminated

  • Asthma Research in Children and Adolescents

    NCT04480242 · start 2017-07-26

    Registered record
    Registry ID
    NCT04480242
    Conditions
    Persistent Asthma; Asthma in Children; Asthma Exacerbation
    Interventions
    Inhaled Corticosteroids (ICs); Fixed-Dose Combination of Inhaled Corticosteroids and Long- Acting Beta-agonist (ICs/LABA); Other treatments; Inhaler device; Regularly monitoring of the Inhalation technique through mobile app
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Active not recruiting
    Start
    2017-07-26
    Completion
    2030-12-31
    Enrolment
    525

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPersistent Asthma; Asthma in Children; Asthma Exacerbation
    InterventionInhaled Corticosteroids (ICs); Fixed-Dose Combination of Inhaled Corticosteroids and Long- Acting Beta-agonist (ICs/LABA); Other treatments; Inhaler device +1 more
    PhaseNot recorded
    Registry statusActive not recruiting

  • Evaluate the Therapeutic Effect of Inhaled Corticosteroid in Asthmatic Children

    NCT03487809 · start 2016-10-22

    Registered record
    Registry ID
    NCT03487809
    Conditions
    Asthma
    Interventions
    Budesonide/Cisclesonide
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Unknown
    Start
    2016-10-22
    Completion
    2025-12-31
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAsthma
    InterventionBudesonide/Cisclesonide
    PhaseNot recorded
    Registry statusUnknown

  • Intralymphatic Immunotherapy for House Dust Mite, Dog, and Cat Allergy Using Tyrosine S® in Allergic Rhinitis

    NCT02665754 · start 2016-07

    Registered record
    Registry ID
    NCT02665754
    Conditions
    Allergic Rhinitis
    Interventions
    ILIT with extract of causal allergen; ILIT with normal saline; Rescue medication for allergic rhinitis
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2016-07
    Completion
    2020-01
    Enrolment
    32

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAllergic Rhinitis
    InterventionILIT with extract of causal allergen; ILIT with normal saline; Rescue medication for allergic rhinitis
    PhasePhase 1
    Registry statusCompleted

  • Efficacy and Safety of Ciclesonide Nasal Spray in Participants With Seasonal Allergic Rhinitis (SAR) in Russia

    NCT02155881 · start 2014-08

    Registered record
    Registry ID
    NCT02155881
    Conditions
    Seasonal Allergic Rhinitis
    Interventions
    Ciclesonide; Ciclesonide Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2014-08
    Completion
    2014-11
    Enrolment
    80

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSeasonal Allergic Rhinitis
    InterventionCiclesonide; Ciclesonide Placebo
    PhasePhase 3
    Registry statusCompleted

  • Effect of High Dose Ciclesonide on Asthma Control

    NCT01455194 · start 2011-11

    Registered record
    Registry ID
    NCT01455194
    Conditions
    Bronchial Asthma
    Interventions
    Ciclesonide
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2011-11
    Completion
    2014-08
    Enrolment
    520

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBronchial Asthma
    InterventionCiclesonide
    PhasePhase 3
    Registry statusCompleted

  • A Safety and Efficacy Study of Ciclesonide Nasal Aerosol in Subjects 6-11 Years With Seasonal Allergic Rhinitis (SAR)

    NCT01458275 · start 2011-11

    Registered record
    Registry ID
    NCT01458275
    Conditions
    Seasonal Allergic Rhinitis
    Interventions
    Ciclesonide nasal aerosol 37 mcg; ciclesonide nasal aerosol 74 mcg; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2011-11
    Completion
    2013-03
    Enrolment
    847

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSeasonal Allergic Rhinitis
    InterventionCiclesonide nasal aerosol 37 mcg; ciclesonide nasal aerosol 74 mcg; Placebo
    PhasePhase 3
    Registry statusCompleted

  • A Safety and Efficacy Study of Ciclesonide Nasal Aerosol in Subjects 6-11 Years With Perennial Allergic Rhinitis (PAR).

    NCT01451541 · start 2011-10

    Registered record
    Registry ID
    NCT01451541
    Conditions
    Perennial Allergic Rhinitis; PAR
    Interventions
    Ciclesonide nasal aerosol 37 mcg; ciclesonide nasal aerosol 74 mcg; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2011-10
    Completion
    2012-12
    Enrolment
    848

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPerennial Allergic Rhinitis; PAR
    InterventionCiclesonide nasal aerosol 37 mcg; ciclesonide nasal aerosol 74 mcg; Placebo
    PhasePhase 3
    Registry statusCompleted

  • Safety Study of the Potential Inhibitory Effects of Ciclesonide Nasal Aerosol on the Hypothalamic-Pituitary-Adrenal Axis in Subjects 6-11 Years With Perennial Allergic Rhinitis

    NCT01378429 · start 2011-07

    Registered record
    Registry ID
    NCT01378429
    Conditions
    Perennial Allergic Rhinitis; PAR
    Interventions
    ciclesonide nasal aerosol; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2011-07
    Completion
    2011-11
    Enrolment
    89

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPerennial Allergic Rhinitis; PAR
    Interventionciclesonide nasal aerosol; Placebo
    PhasePhase 3
    Registry statusCompleted

  • Study of the Effect of Vitamin D as an Add-on Therapy to Corticosteroids in Asthma

    NCT01248065 · start 2011-04

    Registered record
    Registry ID
    NCT01248065
    Conditions
    Asthma
    Interventions
    Vitamin D3; Ciclesonide
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2011-04
    Completion
    2014-01
    Enrolment
    408

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAsthma
    InterventionVitamin D3; Ciclesonide
    PhasePhase 3
    Registry statusCompleted

  • A Study Comparing The Bioequivalence Of Ciclesonide Nasal Spray (Apotex, Inc.) To That Of Omnaris™ Nasal Spray (Sepracor, Inc.) In The Treatment Of Seasonal Allergic Rhinitis

    NCT02273817 · start 2011-03

    Registered record
    Registry ID
    NCT02273817
    Conditions
    Seasonal Allergic Rhinitis
    Interventions
    Ciclesonide nasal spray, 50 μg per actuation.
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2011-03
    Completion
    2011-08
    Enrolment
    580

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSeasonal Allergic Rhinitis
    InterventionCiclesonide nasal spray, 50 μg per actuation.
    PhasePhase 3
    Registry statusCompleted

  • Evaluation of a Novel Questionnaire to Assess Patient Satisfaction With and Preference of Intranasal Corticosteroids for the Treatment of Allergic Rhinitis

    NCT01287364 · start 2011-02

    Registered record
    Registry ID
    NCT01287364
    Conditions
    Perennial Allergic Rhinitis
    Interventions
    ciclesonide hydrofluoroalkane (HFA) nasal aerosol; mometasone nasal inhalation
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2011-02
    Completion
    2011-04
    Enrolment
    185

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPerennial Allergic Rhinitis
    Interventionciclesonide hydrofluoroalkane (HFA) nasal aerosol; mometasone nasal inhalation
    PhasePhase 3
    Registry statusCompleted

  • Omnaris Versus Levocetirizine Phase 4 Study

    NCT01430260 · start 2011-01

    Registered record
    Registry ID
    NCT01430260
    Conditions
    Allergic Rhinitis
    Interventions
    Ciclesonide; Levocetirizine; Ciclesonide & Levocetirizine
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2011-01
    Completion
    2012-07
    Enrolment
    349

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAllergic Rhinitis
    InterventionCiclesonide; Levocetirizine; Ciclesonide & Levocetirizine
    PhasePhase 4
    Registry statusCompleted